SPOTLIGHT -
EP. 1: GOG-0218: Frontline Bevacizumab in Ovarian Cancer
EP. 2: SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
EP. 3: PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
EP. 4: Practical Applications of PRIMA in Ovarian Cancer Management
EP. 5: PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer
EP. 6: Ovarian Cancer: Factors in Deciding on Maintenance Therapy
EP. 7: Ovarian Cancer: What is the Role of HRD Testing?
EP. 8: Treating Ovarian Cancer Based on HRD Status
EP. 9: Ovarian Cancer: Updates to NCCN Guidelines
EP. 10: Ovarian Cancer: Maintenance Following Frontline Bevacizumab
EP. 11: Considerations for the JAVELIN OVARIAN 100 Study
EP. 12: Frontline Ovarian Cancer Management: Ongoing Clinical Trials
EP. 13: PARP Inhibition’s Role in Recurrent Ovarian Cancer
EP. 14: Recurrent Ovarian Cancer: Choosing a PARP Inhibitor
EP. 15: Bevacizumab’s Role in Recurrent Ovarian Cancer
EP. 16: Recurrent Ovarian Cancer: Novel Agents Under Investigation
EP. 17: Novel Combination Strategies in Recurrent Ovarian Cancer
EP. 18: Systemic Management of Ovarian Cancer: Closing Thoughts
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
